BioPharma Dive Apr 6, 2026 Under-the-skin Tepezza comparable to infused version in key study, Amgen says
BioPharma Dive Apr 2, 2026 Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM
BioPharma Dive Apr 1, 2026 Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets
BioPharma Dive Apr 1, 2026 A ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma